CAJ | 학술논문

目的探讨2型糖尿病(T2DM)患者血清中CA242水平与唾液酸及Lewis血型物质的关系.方法用凝集法、ABC-ELISA法、酶法和免疫比浊法分别检测2 000例T2DM患者及500名健康对照者的Lewis血型以及血清中CA242、唾液酸(SA)、糖化血红蛋白(HbAle)水平,并分析它们之间的关系.结果 T2DM患者CA242水平和阳性率分别为(20 470±14 860)U/L、6.0%(121/2 000),明显高于健康对照者的(10 950±8 490)U/L、0.4%(2/500),差异有统计学意义(t′=18.87,χ~2=26.1,P均<0.01).T2DM患者SA水平为(51.5±18.6)μg/L,明显低于健康对照者的(56.3±13.8)μg/L,差异有统计学意义(t′=6.45,P<0.01).CA242阳性T2DM患者的CA242水平与sA呈负相关(r=-0.693,P<0.01),与HbAIc呈正相关(r=0.547,P<0.01).98.3%(119/121)CA242阳性T2DM患者的Lewis血型属于I型链结构.CA242阳性的T2DM患者治疗后,CA242水平显著下降,SA水平明显升高,治疗前后的CA242和SA水平分别为30 570(27 040-42 630)、(22 35013 400)U/I.和(44.5±13.5)、(55.5±17.2)μg/L,差异有统计学意义(U=5.32,t′=5.53,P均<O.01).结论 T2DM患者血清中CA242升高可能是Lewis 务;血型的I型物质与唾液酸非酶促反应的结果,而非恶性升高.通过控制T2DM患者血糖,CA242水平能得到有效控制.
목적 탐토2형당뇨병(T2DM)환자혈청중CA242수평여타액산급Lewis혈형물질적관계.방법 용응집법、ABC-ELISA법、매법화면역비탁법분별검측2 000례T2DM환자급500명건강대조자적Lewis혈형이급혈청중CA242、타액산(SA)、당화혈홍단백(HbAle)수평,병분석타문지간적관계.결과 T2DM환자CA242수평화양성솔분별위(20 470±14 860)U/L、6.0%(121/2 000),명현고우건강대조자적(10 950±8 490)U/L、0.4%(2/500),차이유통계학의의(t′=18.87,χ~2=26.1,P균<0.01).T2DM환자SA수평위(51.5±18.6)μg/L,명현저우건강대조자적(56.3±13.8)μg/L,차이유통계학의의(t′=6.45,P<0.01).CA242양성T2DM환자적CA242수평여sA정부상관(r=-0.693,P<0.01),여HbAIc정정상관(r=0.547,P<0.01).98.3%(119/121)CA242양성T2DM환자적Lewis혈형속우I형련결구.CA242양성적T2DM환자치료후,CA242수평현저하강,SA수평명현승고,치료전후적CA242화SA수평분별위30 570(27 040-42 630)、(22 35013 400)U/I.화(44.5±13.5)、(55.5±17.2)μg/L,차이유통계학의의(U=5.32,t′=5.53,P균<O.01).결론 T2DM환자혈청중CA242승고가능시Lewis 무;혈형적I형물질여타액산비매촉반응적결과,이비악성승고.통과공제T2DM환자혈당,CA242수평능득도유효공제.
Objective To investigate the relationship between levels CA242 , sialic acid and Lewis blood-group substance in type 2 diabetes mellitus (T2DM) patients. Methods Lewis blood group, serum CA242, siaiic acid (SA) and HbAlc levels were separately detected by agglutination test, ABC-ELISA assay, enzymatic method and immunoturbidimetric assay and the correlations between them were analyzed in 2000 T2DM patients and 500 healthy controls. Results The mean level and positive ratio of serum CA242 in T2DM patients were (20 470 ± 14 860) U/L and 6. 0% (121/2 000) , which were obviously higher than those of controls[(10 950 ±8 490) U/L,0.4% (2/500)]. There were significantly statistical differences (t′ = 18. 87,P<0.01,χ~2 =26. 1,P <0.01). The SA level of T2DM patients was(51.5 ± 18.6) μg/L, which was obviously lower than that of controls[ (56.3 ±13. 8) μxg/L] (t′ = 6. 45, P <0. 01). The CA242 levels were negatively correlated with SA ( r = - 0. 693 , P < 0. 01) but positively correlated with HbAl c ( r = 0. 547, P < 0. 01) in CA242-positive T2DM patients.The Lewis blood group in 98. 3% (119/121) CA242 positive T2DM patients belong to type-I chain substrate. After treatment, the CA242 levels were decreased in CA242-positive T2DM patients whereas SA levels were increased obviously. The CA242 and SA levels of pre- and post-therapy were 30 570 (27 040-42 630), (22 350 ± 13 400) U/L and (44. 5 ± 13. 5), (55. 5 ± 17. 2) μg/L, respectively. There were significantly statistical differences ( U = 5. 32, P < 0. 01, t′ =5.53,P<0.01). Conclusions The elevation of serum CA242 levels in T2DM patients is probably due to reaction between type-1 chain substrate and SA by non-enzymatic mode. It is not the consequence ofmalignancy. In T2DM patients, CA242 level can be effectively controlled by regulating blood sugar levels.